Deals
Deal activity by volume related to ESG increased by 50% year-on-year in 2022 in the pharmaceutical industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that ESG accounted for 314 pharmaceutical deals between 2018 and 2022, worth a total value of $131,024m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.
The $60m acquisition of ACT Genomics by Prenetics Global was the largest disclosed deal in 2022, while the $85m acquisition of Notch Therapeutics by Lumira Capital Investment Management was the largest disclosed deal in 2021.
In volume terms, ESG related deal activity decreased by 50% year-on-year in 2022 and by 86% in 2021.
Deal activity related to ESG in the global pharmaceutical industry in the last five years
Top deals related to ESG in the pharmaceutical industry in the last five years
Deal volume by deal type for ESG related deals in the pharmaceutical industry in the last five years
Licensing agreements accounted for the highest number of deals in the last five years, with 176 deals, followed by partnerships (52 deals), and acquisitions (31 deals).
Top financial advisors for ESG related deals by value in the pharmaceutical industry in the last five years
The top financial advisors supporting deals related to ESG in the pharmaceutical industry in the last five years in terms of value were Goldman Sachs International, Deutsche Bank, Morgan Stanley, BNP Paribas, and Barclays Bank.
Top legal advisors for ESG related deals by value in the pharmaceutical industry in the last five years
The top legal advisors supporting deals related to ESG in the pharmaceutical industry in the last five years in terms of value were White & Case, Latham & Watkins, Fried, Frank, Harris, Shriver & Jacobson, Linklaters, and Arthur Cox.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
